tiprankstipranks
Trending News
More News >
BioInvent International AB (SE:BINV)
:BINV

BioInvent International AB (BINV) AI Stock Analysis

Compare
1 Followers

Top Page

SE

BioInvent International AB

(OTC:BINV)

Rating:50Neutral
Price Target:
kr39.00
▲(2.36%Upside)
BioInvent International AB has a low overall score mainly due to significant financial performance issues, including negative earnings and cash flow. Although there is positive technical momentum, the valuation metrics reflect substantial losses. Strategic changes may be needed to address financial sustainability.

BioInvent International AB (BINV) vs. iShares MSCI Sweden ETF (EWD)

BioInvent International AB Business Overview & Revenue Model

Company DescriptionBioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
How the Company Makes MoneyBioInvent International AB generates revenue primarily through partnerships and collaborations with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, where BioInvent provides access to its proprietary technology platforms and expertise in antibody discovery and development in exchange for upfront payments, milestone payments, and royalties on future sales of successfully developed drugs. Additionally, the company may receive funding from research grants and government support, as well as potential earnings from its own clinical-stage drug candidates once they reach the market. Key revenue streams include licensing fees, milestone payments, and royalties from strategic partnerships, which are crucial for financing its research and development activities.

BioInvent International AB Earnings Call Summary

Earnings Call Date:Apr 29, 2025
(Q3-2024)
|
% Change Since: 30.03%|
Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and strategic collaborations, with promising data in lead compounds and strong financial reserves. However, these positives are counterbalanced by decreased net sales, increased operating costs, and significant financial losses.
Q3-2024 Updates
Positive Updates
Positive Data for Lead Compound BI-1206
The company reported additional positive data for their lead compound BI-1206, targeting FcgammaRIIB, especially for the subcutaneous formulation, with 2 complete responses, 3 partial responses, and 3 stable diseases out of 9 evaluable patients.
Progress in BI-1808 and BI-1910 Programs
BI-1808 showed 3 partial responses and 1 stable disease out of 4 evaluable patients in the CTCL cohort. BI-1910 received a Notice of Allowance and showed robust target occupancy in trials.
Successful Subcutaneous Formulation
The subcutaneous (subcu) formulation of BI-1206 showed improved activity and safety profile compared to the intravenous version, eliminating infusion-related reactions.
Strategic Collaborations
New clinical trial collaboration and supply agreements were established with Merck for BI-1607, and with AstraZeneca for BI-1206 in a triplet combination with rituximab and acalabrutinib.
Promising Anti-CTLA-4 Antibody Data
The anti-CTLA-4 antibody in combination with pembrolizumab showed tumor regression in patients who failed previous anti-PD-L1 treatment.
Strong Financial Position
The company has liquid funds of SEK 979 million, providing a financial runway until the end of Q1 2026.
Negative Updates
Decrease in Net Sales
Net sales decreased by SEK 14 million in Q3 2024 compared to Q3 2023, and by SEK 33 million for the January to September period in 2024 compared to the same period in 2023.
Increased Operating Costs
Operating costs increased by SEK 12 million in Q3 2024 compared to Q3 2023, and by SEK 53 million for the January to September period in 2024 compared to the same period in 2023.
Significant Losses
The company reported a loss of SEK 97.2 million for Q3 2024 and a loss of SEK 312.5 million for the January to September period in 2024.
Company Guidance
During the BioInvent Q3 2024 earnings call, CEO Martin Welschof and CFO Stefan Ericsson provided extensive guidance on the company's development programs, highlighting several key metrics. The company reported net sales of SEK 12.8 million for Q3 2024, a decrease from SEK 26.8 million in Q3 2023, primarily due to the absence of a $1 million milestone achieved in the previous year. Operating costs increased to SEK 120 million compared to SEK 108 million in Q3 2023, partly due to higher costs associated with their BI-1607 and BI-1808 programs. The loss for Q3 2024 was reported as SEK 97.2 million. The company emphasized the promising progress of its lead compounds, including BI-1206, BI-1808, and BI-1910, with significant developments in both subcutaneous and intravenous formulations, notably in achieving complete and partial responses in clinical trials. They anticipate further data releases by the end of the year and into 2025, which could drive substantial value and strategic opportunities, including potential partnerships. BioInvent's liquid funds at the end of September amounted to SEK 979 million, providing a runway until Q1 2026, and the management expressed optimism about securing collaborations to bolster their financial position.

BioInvent International AB Financial Statement Overview

Summary
BioInvent International AB faces significant financial challenges, with declining revenues and persistent losses impacting profitability. The balance sheet remains a relative strength due to solid equity and a low debt burden. However, the company's inability to generate positive cash flow from operations raises concerns about its long-term sustainability. Strategic adjustments may be necessary to improve operational efficiency and financial performance.
Income Statement
30
Negative
The company has experienced a severe decline in revenue over the past few years, with TTM (Trailing-Twelve-Months) revenue significantly lower than previous years. Gross profit margins have remained constant at 100%, indicating that all revenue contributes directly to gross profit. However, the net profit margin is deeply negative, reflecting substantial operating losses. The EBIT and EBITDA margins are also negative, highlighting significant operational challenges.
Balance Sheet
60
Neutral
The company maintains a strong equity position with an equity ratio of approximately 89% in the TTM period. The debt-to-equity ratio is low, suggesting limited reliance on debt financing. However, the substantial negative net income impacts the return on equity, which remains negative. The company's cash position remains strong, providing some stability amidst operational challenges.
Cash Flow
35
Negative
Operating cash flow has been consistently negative, indicating that the company is not generating enough cash from operations to cover its expenses. Free cash flow has also declined, reflecting increased operational and capital expenditure pressures. Despite these challenges, the company has managed to maintain a positive cash position through financing activities.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
60.80M44.69M71.46M326.13M19.38M147.37M
Gross Profit
60.80M44.69M71.46M326.13M19.38M147.37M
EBIT
-504.27M-471.06M-369.94M-50.92M-278.35M-75.47M
EBITDA
-484.41M-409.38M-312.71M-27.13M-263.32M-63.99M
Net Income Common Stockholders
-468.06M-429.38M-330.30M-34.09M-278.96M-76.67M
Balance SheetCash, Cash Equivalents and Short-Term Investments
68.85M867.16M1.07B1.02B1.08B729.27M
Total Assets
120.40M989.24M1.40B1.71B1.45B802.64M
Total Debt
0.0017.41M23.24M26.96M28.37M11.60M
Net Debt
-68.85M-417.41M-236.30M-488.08M-882.39M-717.67M
Total Liabilities
32.78M103.42M90.45M106.09M80.32M59.14M
Stockholders Equity
87.62M885.82M1.31B1.61B1.37B743.50M
Cash FlowFree Cash Flow
-445.08M-390.50M-355.00M-53.60M-259.10M-69.32M
Operating Cash Flow
-434.57M-380.47M-341.69M-41.23M-245.84M-62.62M
Investing Cash Flow
449.97M564.35M59.68M-628.85M-467.54M-6.70M
Financing Cash Flow
-8.62M-8.46M23.14M273.49M894.87M644.62M

BioInvent International AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price38.10
Price Trends
50DMA
31.09
Positive
100DMA
29.16
Positive
200DMA
35.96
Positive
Market Momentum
MACD
2.11
Negative
RSI
62.60
Neutral
STOCH
70.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Positive. The current price of 38.1 is above the 20-day moving average (MA) of 33.86, above the 50-day MA of 31.09, and above the 200-day MA of 35.96, indicating a bullish trend. The MACD of 2.11 indicates Negative momentum. The RSI at 62.60 is Neutral, neither overbought nor oversold. The STOCH value of 70.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BINV.

BioInvent International AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
kr1.30B4.81152.78%1533.99%
54
Neutral
$5.28B3.29-45.38%2.80%16.77%-0.08%
50
Neutral
kr2.49B-45.80%-0.57%-39.92%
48
Neutral
kr780.22M-48.22%67.70%
47
Neutral
kr1.16B-42.24%-19.44%
45
Neutral
€2.23B-40.15%63.85%
42
Neutral
kr1.65B
9.53%41.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BINV
BioInvent International AB
38.10
3.00
8.55%
SE:HNSA
Hansa Biopharma AB
24.20
-26.95
-52.69%
SE:SANION
Saniona AB
9.30
6.24
203.43%
SE:VICO
Vicore Pharma Holding AB
9.35
-13.13
-58.40%
SE:XSPRAY
Xspray Pharma AB
31.30
-39.65
-55.88%
SE:SYNACT
SynAct Pharma AB
18.70
11.77
170.00%

BioInvent International AB Corporate Events

BioInvent Showcases BI-1910 Development at PAGE 2025
Jun 4, 2025

BioInvent International AB announced the presentation of a poster at the PAGE 2025 meeting in Thessaloniki, Greece, highlighting the early clinical development of its anti-TNFR2 drug candidate, BI-1910. The company successfully developed a population model to characterize the pharmacokinetics and pharmacodynamics of BI-1910, which will aid in dose selection for upcoming Phase 2a studies. These studies, planned for the second half of 2025, will evaluate BI-1910 as a single agent and in combination with pembrolizumab for various tumor types. The announcement underscores BioInvent’s progress in cancer immunotherapy and its potential impact on clinical utility and market potential.

BioInvent Sells Mezagitamab Rights to XOMA for $30 Million
May 27, 2025

BioInvent International AB has sold its future royalty and milestone rights for the cancer drug mezagitamab to XOMA Royalty for up to USD 30 million. This transaction provides BioInvent with non-dilutive capital to advance its drug development programs and reflects XOMA’s increased interest in mezagitamab, enhancing its royalty portfolio with potential future earnings from the drug’s commercial success.

BioInvent Reports Promising Phase 2a Results for BI-1808 in CTCL
May 14, 2025

BioInvent International AB has announced promising results from its ongoing Phase 2a study of BI-1808, a monotherapy for Cutaneous T-cell Lymphoma (CTCL). The study has shown encouraging clinical activity with one complete response, three partial responses, and four stable diseases among eight evaluable patients. The treatment demonstrated strong immune activation and was well tolerated, with no severe adverse events reported. These findings, to be presented at the EHA 2025 congress, support further development of BI-1808 as a potential novel treatment option for CTCL, reinforced by its recent Fast Track and Orphan Drug Designation by the FDA.

BioInvent Reports Promising Phase 2a Data for NHL Treatment
May 14, 2025

BioInvent International AB announced promising preliminary data from its ongoing Phase 2a study of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL). The data showed a 63% objective response rate among the first eight patients, with two complete responses and three partial responses, indicating potential improvements in treatment outcomes and resistance management. The combination therapy has been well tolerated, and BioInvent plans to advance its clinical development, highlighting the potential impact on NHL treatment and the company’s position in cancer immunotherapy.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.